

Development of lead antibodies targeting an immune-checkpoint inhibitor refractory factor for metastatic non-small cell lung carcinoma

NEX-I



ONCOLOGY	Lead
Product Type	NXI-101 (Fully human anti-ONCOKINE-1-IgG4S228P mAb)
Indication	NSCLC, CRC, Melanoma, etc.
Target	ONCOKINE-1 (code name)
MoA(Mechanism of Action)	<p>NXI-101 is tumormicroenvironment (TME) modulator, which</p> <ul style="list-style-type: none"> - neutralizes the secreted ONCOKINE-1 in TME - activates CD8+ T cells by directly inhibiting MDSC function & recruitment - changes TME from COLD to HOT - blocks tumor’s anti-apoptotic signal - synergizes with anti-PD-1 and activates anti-tumor T cell immunity <p style="text-align: right; font-size: small;">Copyright© 2022 NEX-I. ALL RIGHTS RESERVED</p>
Competitiveness	<p>First-in-Class</p> <p>ONCOKINE-1 is a novel causal factor for immunotherapy resistance which is identified through over 20 different resistant cancer cell lines</p> <p>ONCOKINE-1 is a prognostic and predictive biomarker measurable in blood and tissue</p>
Development Stage	Pre-clinical (GLP Tox)
Route of Administration	Parenteral - Intravenous